STOCKS TELEGRAPH

Tag: APM

  • Here’s What you Should Know About Inclining Premarket Stock of Aptorum Group Ltd. (APM)

    Aptorum Group Ltd. (APM) is a leading biotherapeutics company. It is engaged in the development and commercialization of treatments for oncology and infectious diseases. The company also focuses on its therapeutics platform for gastro and metabolic issues along with women’s health.

    The price of APM stock during the regular trading on January 24, 2022 was $1.62 with 9.46% incline. At last check in the premarket on January 25, 2022, the stock further rocketed by 42.5%.

    APM: Events and Happenings

    On January 20, 2022, APM reported about the grant of Orphan Drug Designation to SACT-1 by FDA. It is utilized in treating patients with Neuroblastoma. The company is also expecting to file IND application to commence phase 1/2 studies. On January 18, 2022, APM reported about the grant of preliminary patent status for the SACT-1 by the US Patent and Trademark Office.

    APM on January 10, 2022, reported that its subsidiary had commenced the clinical authentication of its rapid pathogen diagnostics liquid biopsy technology for diagnosing the pathogens. On January 10, 2022, APM reported about initiation of its cancer and autoimmune development portfolio. On January 10, 2022, APM reported about closure of clinical trials for ALS-4 and evaluating the relative bioavailability and food impact of SACT-1.

    APM on December 3, 2021, reported about the outcomes of 2021 annual general meeting of stockholders held on December 2. The stockholders re-elected all the current management of the company. Along with approving the re-appointment of company’s independent auditors, the stockholders also approved amendments to different articles.

    APM: Key Financials

    On September 15, 2021, APM reported its financial results for the six months ended June 30, 2021. Some of the key updates are as follows.

    Net Loss per Share

    Basic and diluted net loss per share in H1 2021 was $17.1 million or $0.47 compared to $7.0 million or $0.21 for the same period in 2020.

    Assets

    Total current assets of the company in first half of 2021 were $21.9 million.

    Conclusion

    APM stock is 39% down the past half yearly period due to the economic restrictions imposed by the global pandemic. The current premarket surge in stock is the result of uncertain reasons as the company has not reported any recent news regarding its activities. The financial specialists are expecting more accomplishments from the company in the coming days.

  • Everything you need to know about Aptorum Group Limited [APM] RPIDD Deal

    Everything you need to know about Aptorum Group Limited [APM] RPIDD Deal

    It’s a good start to the day for Aptorum Group Limited [NASDAQ:APM] investors. The stock has been gaining quite strongly since early morning and was up by over 600% just before markets opened.

    The massive gains come after the company announced that it had launched an infectious disease liquid biopsy startup. The company also announced that it landed an exclusive in-license deal for the development of molecular-based rapid pathogen diagnostics tools from Singapore based Accelerate Technologies. The tools developed under the co-development deal will be used in tracking pathogenic genomes.

    Aptorum intends to leverage the deal to aggressively grow market share in the molecular tools diagnostics market. This is a big deal considering that the molecular diagnostics market is expected to hit a valuation of $13.8 billion by the year 2025. It is also noteworthy that around 60% of this $13.8 billion market is expected to be driven by infectious disease, an area that the company intends to reach using high-tech RPIDD technologies.

    RPIDD is a technology that can identify and detect pathogens, with a high degree of accuracy. It has the capacity to identify both known pathogens and emerging ones such as coronaviruses and bacteria that are resistant to antibiotics. It is also important to note that this technology can do this cost-effectively and without bias, by using a liquid biopsy, software analytic and genome sequencing.

    Through its subsidiary called Aptorum Innovations Pte Ltd, Aptorum Group will have exclusive licensing and commercialization rights to the RPIDD technology that is being developed in partnership with Accelerate Technology. Aptorum Group has also stated that it wants to start developing RPIDD-driven infectious disease laboratories in the next 2 years.

    The company added that one of these labs would be located in Singapore and that it would work with hospitals and other health facilities in the country. Other locations where it intends to set up the labs are in Australia and Hong Kong.

    Commenting on the development, the company’s CEO Dr Clark Cheng stated that with the global disruption caused by COVID-19, and the global issue of antibiotic resistance all played a role in the company’s decision to bolster its capacity in biopsy diagnostics. He added that the mortality rates of infectious diseases was quite high and necessitated action. He further stated that the company, through its subsidiary would roll out RPIDD commercially by setting proprietary labs.

    About Aptorum Group Limited

    Aptorum Group Limited is a pharma company that develops treatments for unmet needs. It is based in London, United Kingdom.